Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone health in cancer patients".
Press Release Dec 10 2025
Filed with NSE · · 3 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 09 2025
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Press Release Dec 04 2025
- Press Release Nov 27 2025
- Press Release Nov 26 2025
Later from Zydus Lifesciences
- Press Release Dec 15 2025
- Zydus Lifesciences Limited Press Release Dec 19 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
- Press Release Dec 23 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences